Clinical Trials Browser

Enrolling by invitation × INDUSTRY × Carcinoma, Non-Small-Cell Lung × Clear all

NCT07218003 2026-03-23

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

BreastGastrointestinalGenitourinaryGynecologicThoracic

Esophageal Squamous Cell Carcinoma, Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT06281964 2025-12-16

KANNON-2

Phase 3 Enrolling by invitation

327 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07285434 2025-12-16

Microlyvaq™

Phase EARLY_PHASE1 Enrolling by invitation

90 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06603987 2025-11-19

Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA

Phase 1/2 Enrolling by invitation

30 enrolled

BreastGastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neurofibrosarcoma

NCT06885424 2025-07-15

DESCENT-1

Enrolling by invitation

400 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Kidney Neoplasms, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06759857 2025-01-06

FHND9041

Phase 3 Enrolling by invitation

350 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung